Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Q1

<< Previous

Bullboard Posts

Next >>

Comment by stockfyon Jun 09, 2021 2:10am

178 Views

Post# 33353420

RE:RE:RE:Q1

Well said.

Where are now those cluless posters of this board who blindly followed a clueless analyst Justin Keywood from Stifel and his highly inaccurate forecasts?

Where are now the clueless posters who blindly used Keywood's highly inaccurate projections as BIBLE and dumped CPH at $0.90 and $0.80 a few months ago?

Northforce13 wrote:

After scratching my head a bit, another positive is that I expected earnings to start declining this quarter, and subsequent ones, until something comes along down the road. Yet earnings were much stronger than expected, excluding the legal costs.

The big share price jump appears to have been the result of someone with RBC as a broker sucking up shares aggressively at 1.40+ as of 3:00 PM and on into close. Intriguing -)

Pretty quiet boards